Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Stage of Development | 9 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Therapy Area | 10 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Indication | 11 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Companies | 15 | 2 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Products under Development by Universities/Institutes | 17 | 2 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Therapeutics Assessment | 19 | 7 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Companies Involved in Therapeutics Development | 26 | 14 |
| Aduro BioTech, Inc. | 26 | 1 |
| Agenus, Inc. | 27 | 1 |
| Alligator Bioscience AB | 28 | 1 |
| AlphaMab Co., Ltd | 29 | 1 |
| CytomX Therapeutics, Inc. | 30 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 31 | 1 |
| JHL Biotech, Inc. | 32 | 1 |
| Lytix Biopharma AS | 33 | 1 |
| Novartis AG | 34 | 1 |
| OncoImmune, Inc. | 35 | 1 |
| Pfizer Inc. | 36 | 1 |
| Premier Biomedical Inc. | 37 | 1 |
| PsiOxus Therapeutics Limited | 38 | 1 |
| Sutro Biopharma, Inc. | 39 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Drug Profiles | 40 | 19 |
| ADC-1015 Drug Profile | 40 | 1 |
| AGEN-2041 Drug Profile | 41 | 1 |
| Anti-CTLA4 + LTX-315 Drug Profile | 42 | 1 |
| Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor Drug Profile | 43 | 1 |
| Biologic to Antagonize CTLA4 for Solid Tumor Drug Profile | 44 | 1 |
| Biologics to Target CTLA4 and TNF Alpha Drug Profile | 45 | 1 |
| JMW-3B3 Drug Profile | 46 | 1 |
| KN-044 Drug Profile | 47 | 1 |
| Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology Drug Profile | 48 | 1 |
| Monoclonal Antibody Conjugate to Target CTLA-4 for Oncology Drug Profile | 49 | 1 |
| Monoclonal Antibody to Antagonize CTLA-4 for Oncology Drug Profile | 50 | 1 |
| Monoclonal Antibody to Antagonize CTLA4 for Breast Cancer Drug Profile | 51 | 1 |
| Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile | 52 | 1 |
| Monoclonal Antibody to Antagonize CTLA4 for Oncology Drug Profile | 53 | 1 |
| Monoclonal Antibody to Target GLUT2 and CTLA4 for Type 1 Diabetes Drug Profile | 54 | 1 |
| Monocloncal Antibody to Inhibit CTLA-4 for Oncology Drug Profile | 55 | 1 |
| ONC-392 Drug Profile | 56 | 1 |
| Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors Drug Profile | 57 | 1 |
| Small Molecule to Target CTLA4 and IFNGR for RRMS Drug Profile | 58 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Dormant Projects | 59 | 1 |
| Cytotoxic T-Lymphocyte Protein 4 (CTLA-4 or CD152) Featured News &Press Releases | 60 | 1 |
| Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting | 60 | 1 |
| Appendix | 61 | 2 |
| Methodology | 61 | 1 |
| Coverage | 61 | 1 |
| Secondary Research | 61 | 1 |
| Primary Research | 61 | 1 |
| Expert Panel Validation | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |